|1.||Supuran, Claudiu T: 6 articles (12/2015 - 08/2006)|
|2.||Hainer, Vojtech: 5 articles (10/2014 - 11/2006)|
|3.||Astrup, Arne: 5 articles (06/2014 - 12/2003)|
|4.||Eckel, Robert H: 3 articles (12/2014 - 06/2011)|
|5.||Scozzafava, Andrea: 3 articles (01/2013 - 08/2006)|
|6.||Bays, Harold: 3 articles (08/2007 - 01/2002)|
|7.||Nakazato, Masamitsu: 2 articles (12/2015 - 02/2013)|
|8.||Blanch, Natalie: 2 articles (09/2015 - 01/2015)|
|9.||Wong, I C K: 2 articles (06/2015 - 08/2010)|
|10.||Viner, R M: 2 articles (06/2015 - 08/2010)|
01/01/2007 - "Finally, the efficacy of antiobesity agents and their value in the treatment of obesity are assessed in comparison with other therapeutic approaches, such as surgery and changes in lifestyle."
01/01/2015 - "Effective and safe antiobesity drugs are still needed in face of the obesity pandemic worldwide. "
12/01/2014 - "Inhibition of TAG synthesis will become an efficacious treatment strategy for obesity and our excessive obesity model will provide a very useful tool for discovery of new anti-obesity drugs in the future. "
01/01/2009 - "Despite this risk, the prevalence of obesity continues to increase worldwide, and there is a growing demand for safe and effective antiobesity drugs. "
01/01/2005 - "Our results suggest that CS may be useful in the treatment of obesity and related disorders as anti-obesity agents."
|2.||Weight Loss (Weight Reduction)
01/01/2014 - "Anti-obesity drugs, meal replacements, and high-protein diets were associated with improved weight-loss maintenance after a VLCD/LCD period, whereas no significant improvements were seen for dietary supplements and exercise."
01/01/2014 - "Compared with controls, anti-obesity drugs improved weight-loss maintenance by 3.5 kg [95% CI: 1.5, 5.5 kg; median duration: 18 mo (12-36 mo)], meal replacements by 3.9 kg [95% CI: 2.8, 5.0 kg; median duration: 12 mo (10-26 mo)], and high-protein diets by 1.5 kg [95% CI: 0.8, 2.1 kg; median duration: 5 mo (3-12 mo)]. "
05/01/2014 - "Although these agents lead to clinically important weight loss when used as monotherapy, the use of antiobesity drugs as adjunctive therapy post intensive lifestyle intervention could prove to be the most successful strategy. "
01/01/2014 - "This weight reduction is moderate but similar to other antiobesity drugs. "
12/01/2013 - "With antiobesity agents, weight loss can emerge from an array of metabolic, cognitive and behavioural changes that translate into weight change over time. "
|3.||Binge-Eating Disorder (Binge Eating Disorder)
01/01/2002 - "There are scant data about the efficacy of the novel antiobesity agents for binge-eating disorder. "
01/01/2015 - "The data emerging from this study seem to show that, at least in the short term, some specific medications within the classes of antidepressants, anticonvulsants, and antiobesity agents may prove promising in achieving the main objectives in the treatment of binge eating disorder: reducing the frequency of binge eating, reducing weight, and improving the associated psychopathology. "
08/01/2003 - "For binge eating disorder, studies have examined the efficacy of antidepressants (tricyclic antidepressants, selective serotonin re-uptake inhibitors and serotonin/noradrenaline re-uptake inhibitors), antiobesity agents (sibutramine) and antiepileptics associated with weight loss (topiramate), with some evidence of efficacy for these agents."
|4.||Body Weight (Weight, Body)
03/01/2012 - "Altogether, our findings strongly suggest that 2 compounds are novel PTP1B inhibitors and might be considered as anti-obesity agents that are effective for suppressing body weight gain and improving lipid homeostasis."
12/01/2015 - "Because it is often difficult to reduce body weight using only present non-invasive therapies, clarification of appetite mechanisms and development of novel anti-obesity drugs with few side effects are needed."
01/01/2015 - "Interventions for body weight management, including advice, referrals and prescription of antiobesity drugs, were evaluated. "
12/01/2013 - "The physiological systems that regulate body weight are thus of great interest as targets for anti-obesity agents. "
10/01/2013 - "Successful development of antiobesity agents requires detailed knowledge of neural pathways controlling body weight, eating behavior, and peripheral metabolism. "
|5.||Metabolic Diseases (Metabolic Disease)
09/07/2013 - "As obesity and its associated metabolic diseases become a worldwide epidemic, the demand for novel anti-obesity agents is increasing. "
09/01/2002 - "It is anticipated that new anti-obesity drugs for this serious, multifaceted metabolic disease will become as safe and effective and as medically accepted as the treatment of other metabolic disorders such as hypertension, dyslipidaemia or Type 2 diabetes mellitus. "
08/01/2007 - "Weight loss through improved nutrition, increased physical activity, and weight loss agents (ie, orlistat and sibutramine) improves adiposopathy and improves many metabolic diseases whose prevalence are directly associated with an increase in body fat and sedentary lifestyle. "
|5.||Anticonvulsants (Antiepileptic Drugs)
|6.||Antidepressive Agents (Antidepressants)
|8.||Serotonin (5 Hydroxytryptamine)
|1.||Drug Therapy (Chemotherapy)
|5.||Gastroplasty (Vertical-Banded Gastroplasty)